# ROIVANT SCIENCES LTD. (ROIV) · Edgar & Edgarette company card

> Roivant Sciences (ROIV) saw revenue fall 71.6% in FY2026 to $8 million, operating margin -6236% against a -3.8% median for pharmaceutical preparations, equity 79.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1635088 · fiscal year ended 2026-03-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ROIV) · [JSON](https://www.pops4.com/boards/company/ROIV.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $8M |
| Revenue growth, 1 year | -71.6% |
| Revenue growth per year | -37.8% |
| Operating margin | -6235.7% (prior year -3453.3%) |
| Net margin | -4817.3% |
| Operating cash flow | −$750M |
| Capital spending | $8M |
| Free cash flow | −$759M |
| Cash | $1.4B |
| Long-term debt | — |
| Total assets | $5.7B |
| Total equity | $4.5B |
| Equity ÷ assets | 79.3% |
| Return on equity | -8.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 16.14 (safe zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -6235.7% in FY2026; revenue is hard to predict: its 80% range is ±84%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $8.3M (FY2026). Experience: revenue down 71.6% on the year, down 37.8% a year over 4 years; operating margin -6235.7%, down from -3453.3%. Soundness: equity 79.3% of assets, return on equity -8.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.1M and $12.6M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $961K to $15.0M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -6235.7% against a -3.8% median; growth -71.6% against 13.7%.

Range logged 2026-09-29, receipt 63b9e36c1a328863, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-10-21 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1635088/000114036126040332/0001140361-26-040332-index.htm)
- 8-K · filed 2026-09-18 · 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000095/0001635088-26-000095-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/0001140361-26-035859-index.htm)
- 8-K · filed 2026-08-28 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1635088/000114036126034854/0001140361-26-034854-index.htm)
- 8-K · filed 2026-08-27 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1635088/000114036126034735/0001140361-26-034735-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/0001635088-26-000090-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001635088.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1635088

## Cite

POPS4, Edgar & Edgarette: ROIVANT SCIENCES LTD. (ROIV) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ROIV. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.